Researchers from Ningbo University Publish New Studies and Findings in the Area of Calcium Channel Blocking Agents (Optimization of a sensitive and reliable UPLC-MS/MS method to simultaneously quantify almonertinib and HAS-719 and its...).

Researchers from Ningbo University have conducted a study on calcium channel blocking agents, specifically focusing on the drug almonertinib and its metabolite HAS-719. The study optimized a UPLC-MS/MS method to quantify these compounds and investigated drug-drug interactions between almonertinib and nicardipine. Results showed that nicardipine could inhibit the metabolism of almonertinib in both in vitro and in vivo experiments. This research provides valuable insights into the pharmacokinetics of these drugs and their potential interactions. [Extracted from the article]

Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)